ERBB2 and breast carcinoma: Together these results indicate that loss of PRLR expression in HR+ and HER2-E breast cancer cells results in increased survival, migratory, and invasive capacities, suggesting that PRLR expression endow breast cancer cells with a less aggressive phenotype, thereby limiting their tumorigenic properties.